Daniel is an ARC Future Fellow and leading the glycomics/glycoproteomics initiative at the ACRF International Centre for Cancer Glycomics, Institute for Glycomics, Griffith University in Queensland, Australia. His research interest is in understanding the glyco-language and its variations involved in cancer, immunity and infectious diseases. He and his team have been developing and applying cutting-edge glycomics and glycoproteomics for clinical applications and integrating glycomics and glycoproteomics data into integrated multi-omics workflows.

His career took him from Vienna to Macquarie University, Sydney, before starting his independent career in 2010 as a group leader at the Max Planck Institute for Colloids and Interfaces, Germany. Daniel returned to Australia in 2017 to establish and lead a new cancer and infectious disease glycomics and glycoproteomics laboratory at the Institute for Glycomics, Griffith University. These efforts have made it possible that in 2022, supported by multi-million investment from the Australian Cancer Research Foundation (ACRF) and Griffith University, the new ACRF International Centre for Cancer Glycomics could be established. This unique facility provides a bridge between basic and applied medical research with a specific focus on carbohydrates, the fourth major class of biomolecules essential for life.